CHRS
HEALTHCARECoherus Biosciences Inc
$1.75-0.04 (-2.23%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CHRS Today?
No stock-specific AI insight has been generated for CHRS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.71$2.62
$1.75
Fundamentals
Market Cap$262M
P/E Ratio—
EPS$-1.56
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin4.0%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding149.9M
CHRS News
20 articles- Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?Yahoo Finance·May 5, 2026
- Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026Yahoo Finance·May 4, 2026
- Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?Yahoo Finance·Apr 16, 2026
- Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why – CorrectedYahoo Finance·Apr 10, 2026
- Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution RiskYahoo Finance·Apr 1, 2026
- Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Mar 25, 2026
- Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Mar 19, 2026
- Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.Marketbeat·Mar 14, 2026
- Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...Yahoo Finance·Mar 10, 2026
- Coherus Oncology Q4 Earnings Call HighlightsMarketbeat·Mar 9, 2026
- Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 9, 2026
- Coherus Oncology: Q4 Earnings SnapshotYahoo Finance·Mar 9, 2026
- Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 9, 2026
- Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data CatalystsMarketbeat·Mar 8, 2026
- How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation RisksYahoo Finance·Mar 5, 2026
- Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026Yahoo Finance·Mar 2, 2026
- Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 26, 2026
- Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings EstimatesYahoo Finance·Feb 24, 2026
- Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass EstimatesYahoo Finance·Feb 24, 2026
- Coherus Oncology to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
All 20 articles loaded
Price Data
Open$1.74
Previous Close$1.79
Day High$1.80
Day Low$1.74
52 Week High$2.62
52 Week Low$0.71
52-Week Range
$0.71$2.62
$1.75
Fundamentals
Market Cap$262M
P/E Ratio—
EPS$-1.56
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin4.0%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding149.9M
About Coherus Biosciences Inc
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—